<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050764</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-15919</org_study_id>
    <secondary_id>BMT204</secondary_id>
    <secondary_id>SU-03312009-2059</secondary_id>
    <nct_id>NCT01050764</nct_id>
  </id_info>
  <brief_title>Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells</brief_title>
  <official_title>A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Everett Meyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hematologic malignancies will receive myeloablative chemotherapy followed by
      stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by
      apheresis from a filgrastim- (G-CSF)-mobilized haploidentical related-donor, ie,
      hematopoietic peripheral blood stem cell transplant (HSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is dose-escalation study intended to evaluate the use of classification determinant
      15-positive (CD15+), CD4+, CD127dim, and FoxP3+ regulatory T-cells (T-reg cells) supplemented
      by conventional T-cells (T-con cells), to enhance the efficacy of allogeneic (CliniMACS CD34+
      selected) hematopoietic stem cell transplantation (allo-HSCT), in the setting of leukemia,
      lymphoma, and myelodysplastic syndrome (MDS). This study investigates amelioration of the
      impaired immune recovery and address the significant relapse incidence in the haploidentical
      HSCT setting.

      Pre-transplant myeloablative conditioning will be melphalan; thiotepa; fludarabine and rabbit
      antithymocyte globulin (rATG).

      Stem cell rescue will be with CD34+ selected cells. The rescue infusion will be supplemented
      with infusions of regulatory T-cells (T-reg) and conventional T-cells (T-con) from the same
      donor collection, on Treatment Days 14 and 16 respectively. CD34+ cell infusion day is
      Treatment Day 0.

      T-reg cells are those cells enriched by immunomagnetic selection of CD25+ cells, and further
      purified by flow cytometric cell sorting for the CD15+, CD4+, CD127dim, FoxP3+ cell
      population. These cells are an enriched but naturally-occurring T-cell population.

      T-con cells are unseparated/unfractionated cells, ie, as collected by the peripheral blood
      stem cells apheresis procedure.

      Post-transplant follow-up is for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells</measure>
    <time_frame>30 days after HSCT infusion</time_frame>
    <description>The maximum-tolerated dose (MTD) was to be determined based on the safety and feasibility observed for a pre-determined set of cellular dose level combinations of regulatory T-cells (T-reg) and conventional T-cells (T-con).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-Host-Disease (aGvHD)</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome was incidence of grade 3 or 4 acute graft-vs-host-disease (aGvHD), reported as the number of participants developing grade 3 or 4 aGvHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS), 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed as subjects remaining alive 12 months after CD34+ cell infusion (ie, excludes death due to any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>25 months</time_frame>
    <description>Reported as the median overall survival (OS) in months from infusion of the hematopoietic stem cells (HSCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Measure the Incidence and Severity of Acute and Chronic GvHD</measure>
    <time_frame>1 year</time_frame>
    <description>Population of participants that received HSCT and T-reg plus T-con, and developed actue, chronic, or any graft vs host disease (GvHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Infections</measure>
    <time_frame>1 year</time_frame>
    <description>Serious infections are reported as the number of participants experienced serious infections.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia, Acute</condition>
  <condition>Chronic Myelogenous Leukemia (CML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Non-Hodgkin Lymphoma (NHL)</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regulatory T-cells</intervention_name>
    <description>To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:
Cohort 1
T-reg: 1 x 10e5/kg
T-con: 3 x10e5/kg
Cohort 2
T-reg: 3 x 10e5/kg
T-con: 1 x 10e6/kg
Cohort 3
T-reg: 1 x 10e6/kg
T-con: 3 x 10e6/kg
Cohort 4
T-reg: 3 x 10e6/kg
T-con: 1 x 10e7/kg</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>T-reg cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional T-cells</intervention_name>
    <description>These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>T-con cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>L-PAM</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Phenylalanine Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>thiophosphamide</other_name>
    <other_name>TESPA</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludarabine 5'-monophosphate</other_name>
    <other_name>FAMP</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin, rabbit</intervention_name>
    <description>Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>rATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CliniMACS CD34 Reagent System</intervention_name>
    <description>An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.</description>
    <arm_group_label>T-reg Cell Infusion after Allogeneic Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        RECIPIENT

          -  Histopathologically-confirmed:

          -  Acute leukemia (in first remission with poor risk factors and molecular prognosis)

          -  Acute myelogenous leukemia (AML) with -5,-7, t (6;9), tri8, -11

          -  Acute lymphoblastic leukemia (ALL) with Ph+ t (9;22), t (4;22), (q34;q11)

          -  Acute leukemia with refractory disease or &gt; Complete Remission (CR) 1

          -  Chronic myelogenous leukemia (CML) (accelerated, blast or second chronic phase)

          -  Myelodysplastic syndrome (in high and high intermediate risk categories)

          -  Non-Hodgkin's lymphoma (NHL) with poor risk features and not suitable for autologous
             transplantation

          -  Refractory Chronic lymphocytic leukemia (CLL)

          -  At least 21 days from the end of most recent prior therapy to start of the transplant
             conditioning regimen

          -  Must be &lt; 60 years old at time of registration.

          -  Karnofsky Performance Status (KPS) &gt; 70%

        Must have related donor who is:

          -  Genotypically human leukocyte antigen (HLA) -A, B,C and DR beta 1 (DRB1), DQ loci
             haploidentical to the recipient (but differing for 2 to 3 HLA alleles on the unshared
             haplotype in the graft-versus-host disease (GvHD) direction)

          -  No HLA-matched sibling or matched-unrelated donor is identified.

          -  Adequate cardiac and pulmonary function (left ventricular ejection fraction (LVEF) &gt;
             45%, diffusing capacity of the lungs for carbon monoxide (DLCO) &gt;50% corrected for
             hemoglobin)

          -  Serum creatinine &lt; 1.5 mg/dL OR Creatinine clearance &gt; 50 mL/min for those above serum
             creatinine at least 1.5 mg/dL

          -  Serum bilirubin &lt; 2.0 mg/dL

          -  Alanine transaminase (ALT) &lt; 2x upper normal limit (ULN) (unless secondary to disease)

          -  No prior myeloablative therapy or hematopoietic cell transplantation

        DONOR:

          -  Age ≤ 70 years

          -  Weight ≥ 25 kg.

          -  Medical history and physical examination confirm good health status as defined by
             institutional standards

          -  Seronegative for HIV Ag within 30 days of apheresis collection for:

          -  Hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR) +

          -  Hepatitis C ab or PCR+

          -  Genotypically haploidentical as determined by HLA typing

          -  Female donors (child-bearing potential) must have a negative serum or urine beta-human
             chorionic gonadotropin (HCG) test within 3 weeks of mobilization

          -  Capable of undergoing leukapheresis

          -  Has adequate venous access

          -  Willing to undergo insertion of a central catheter if leukapheresis via peripheral
             vein is inadequate

          -  Capable of agreeing to second donation of peripheral blood progenitor cell (PBPC) (or
             a bone marrow harvest) should the patient fail to demonstrate sustained engraftment
             following the transplant

          -  Institutional review board (IRB)-approved consent form signed by donor or legal
             guardian &gt; 18 years of age

        Donor Selection in the priority order:

          -  Recipient's biological mother preferred, if available

          -  Other available haploidentical donors will be selected based upon the presence of
             natural killer (NK) alloreactivity between donor and recipient by high-resolution HLA
             typing of the C locus. An NK-alloreactive donor will be preferentially chosen.
             Recipients lacking a killer immunoglobulin-like receptor (KIR)-ligand present in the
             donor along with the corresponding KIR defines &quot;NK alloreactivity&quot;.

          -  If more than one NK-alloreactive donor is available, preference is to cytomegalovirus
             (CMV)-seronegative donor

        Exclusion Criteria

        RECIPIENT:

          -  Suitable candidate for autologous transplantation or allogeneic transplantation with
             an available matched-related or matched-unrelated donor

          -  Seropositive for:

          -  HIV ab

          -  Hepatitis B sAg or PCR+

          -  Hepatitis C ab or PCR+

          -  History of invasive Aspergillosis

          -  Any active, uncontrolled bacterial, viral or fungal infection

          -  Uncontrolled central nervous system (CNS) disease involvement

          -  Lactating female

        DONOR:

          -  Evidence of active infection or viral hepatitis

          -  Factors of increased risk for complications from leukapheresis or granulocyte-colony
             stimulating factor (G-CSF) therapy

          -  Lactating female

          -  HIV-positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett H Meyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Everett Meyer</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine (Blood and Marrow Transplantation)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
          <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received HSCT Graft</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Infusion of T-reg Cells</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Infusion of T-con Cells</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death, before HSCT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Donor mobilization failure, death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death, after HSCT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
          <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells</title>
        <description>The maximum-tolerated dose (MTD) was to be determined based on the safety and feasibility observed for a pre-determined set of cellular dose level combinations of regulatory T-cells (T-reg) and conventional T-cells (T-con).</description>
        <time_frame>30 days after HSCT infusion</time_frame>
        <population>Includes all participants that received HSCT</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells</title>
          <description>The maximum-tolerated dose (MTD) was to be determined based on the safety and feasibility observed for a pre-determined set of cellular dose level combinations of regulatory T-cells (T-reg) and conventional T-cells (T-con).</description>
          <population>Includes all participants that received HSCT</population>
          <units>cells/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">GvHD was within parameters to continue, but the study was terminated due to poor outcomes prior to sufficient accrual to set the MTD, even at the only dose level tested (1x10e5/kg T-reg cells + 1x10e5/kg T-con cells). Primary outcome result is null.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-Host-Disease (aGvHD)</title>
        <description>The primary outcome was incidence of grade 3 or 4 acute graft-vs-host-disease (aGvHD), reported as the number of participants developing grade 3 or 4 aGvHD.</description>
        <time_frame>1 year</time_frame>
        <population>Population of participants that received HSCT and T-reg plus T-con</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-Host-Disease (aGvHD)</title>
          <description>The primary outcome was incidence of grade 3 or 4 acute graft-vs-host-disease (aGvHD), reported as the number of participants developing grade 3 or 4 aGvHD.</description>
          <population>Population of participants that received HSCT and T-reg plus T-con</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS), 1 Year</title>
        <description>Assessed as subjects remaining alive 12 months after CD34+ cell infusion (ie, excludes death due to any cause)</description>
        <time_frame>1 year</time_frame>
        <population>Population of participants that received HSCT and T-reg plus T-con</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS), 1 Year</title>
          <description>Assessed as subjects remaining alive 12 months after CD34+ cell infusion (ie, excludes death due to any cause)</description>
          <population>Population of participants that received HSCT and T-reg plus T-con</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS)</title>
        <description>Reported as the median overall survival (OS) in months from infusion of the hematopoietic stem cells (HSCT)</description>
        <time_frame>25 months</time_frame>
        <population>Population of participants that received HSCT and T-reg plus T-con</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS)</title>
          <description>Reported as the median overall survival (OS) in months from infusion of the hematopoietic stem cells (HSCT)</description>
          <population>Population of participants that received HSCT and T-reg plus T-con</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure the Incidence and Severity of Acute and Chronic GvHD</title>
        <description>Population of participants that received HSCT and T-reg plus T-con, and developed actue, chronic, or any graft vs host disease (GvHD)</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Incidence and Severity of Acute and Chronic GvHD</title>
          <description>Population of participants that received HSCT and T-reg plus T-con, and developed actue, chronic, or any graft vs host disease (GvHD)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any GvHD (actue + chronic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Infections</title>
        <description>Serious infections are reported as the number of participants experienced serious infections.</description>
        <time_frame>1 year</time_frame>
        <population>Population of participants that received HSCT and T-reg plus T-con</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
            <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Infections</title>
          <description>Serious infections are reported as the number of participants experienced serious infections.</description>
          <population>Population of participants that received HSCT and T-reg plus T-con</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic T-Cell Infusion After Stem Cell Transplant (SCT)</title>
          <description>Allogeneic, haploidentical hematopoietic stem cell transplant (allo-HSCT) of bone marrow and/or peripheral blood stem cells, followed by infusion of regulatory T-cells (T-reg) plus conventional CD4 and CD8 T-cells (T-con)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis, hemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Donor mobilization failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft vs host disease (aGvHD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chronic graft vs host disease (cGvHD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progressive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Progressive refractory leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis, hemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cystitis, BK-virus-induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis, hemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft vs host disease (aGvHD), skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Acute graft vs host disease (aGvHD), gut</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Acute graft vs host disease (aGvHD), liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, streptococcus mitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Everett H Meyer, MD, PhD; Assistant Professor of Medicine</name_or_title>
      <organization>Stanford University Medical Center</organization>
      <phone>650-725-5816</phone>
      <email>evmeyer@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

